[1] |
LI Xinyu, HUANG Xin.
State of clinical application of meloxicam
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
|
[2] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|
[3] |
XING Kai, GONG Jinyu, LUO Jianquan.
Advances on pharmacogenomics of diuretics-related adverse reactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
|
[4] |
LIN Zhong, XIE Qunli, DAI Shuping, CHEN Jing, LIN Feiyang, ZHU Yanwu, YU Guoliang, ZHANG Yuanhuai, CUI Ke.
Population pharmacokinetics of Linezolid in Chinese adult infection patients#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 992-999.
|
[5] |
ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian.
Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.
|
[6] |
WANG Mengzhi, WEI Yuguang, HUANG Xiaoling.
Analysis of rational usage of meropenem in our hospital
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 937-941.
|
[7] |
ZHONG Ling, SHAO Hua, CHEN Yan, HU Linlin, YU Feng.
Advance in linezolid-induced thrombocytopenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1196-1200.
|
[8] |
XU Jia, HUANG Qi, YANG Zhiling .
Evaluation of clinical rationality of linezolid in our hospital in 2016
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 110-115.
|
[9] |
ZHOU Shuzhen, GAO Yunyun, XIE Jing, GAO Mengfei.
Clinical trial of minocycline hydrochloride combined with vitapex paste in the treatment of persistent apical periodontitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 170-173.
|
[10] |
LI Chun-xing, FU Qiang, ZHU Zhu.
The tissue penetration and pharmacodynamics of linezolid in the infected tissues
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 349-355.
|
[11] |
JIN Yan-jie, ZHANG Jing, LU Ke-peng, LIU Qian, LIN Li-min, SONG Hong-tao.
Linezolid pharmacokinetics/pharmacodynamics and the development of dosage regimen design optimization
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1429-1434.
|
[12] |
LI Su-xia, YANG Xiao-lei, CHEN Su-xiu, LIU Jie-fan, QUAN Shi-chao.
Efficacy and safety of gefitinib treated elded-patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1410-1413.
|
[13] |
LUO Jian-quan, ZHANG Wei.
Research progress on human leucocyte antigen gene polymorphisms and drug adverse reactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 828-834.
|
[14] |
LIANG Bei-bei, WANG Rui, BAI Nan, CAI Yun.
Mutant prevention concentrations study of linezolid and vancomycin against methicillin-resistant staphylococcus aureus isolates
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 251-254.
|
[15] |
LIANG Bei-bei, WANG Rui.
Study on in vitro antimicrobial activity of linezolid, vancomycin and other antibacterials against 111 methicillin resistant staphylococcus aureus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1044-1047.
|